Darifenacin in the treatment of overactive bladder: dose–response effects on urinary symptoms in phase III trials
Hill S1, Khullar V2, Quebe-Fehling E3, Steel M3 1. Department of Obstetrics and Gynaecology, Queen’s Park Hospital, Blackburn, UK, 2. Department of Urogynaecology, St. Mary's Hospital Imperial College, London, UK, 3. Novartis Pharma AG, Basel, Switzerland
|
|
Abstract 145
|
|
|
Non Discussion Posters
Scientific Non Discussion Poster Session 17
|
|
|